Pharma BD Deal Intelligence
A cash-flow cleanup deal that paid off: eliminating the Xolair royalty stream looks like a bargain now that Xolair is a multi-billion-dollar-a-year blockbuster.
Full analysis, sources & comparables →Genentech's primary motive was financial: by acquiring Tanox, Genentech eliminated its royalty obligation and captured Novartis profit-share/royalty flow, with…
Genentech completed the $919M Tanox acquisition at $20/share — a 47% premium — marking the company's first-ever M&A transaction and consolidating Xolair…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Genentech's first-ever acquisition; Xolair (omalizumab) royalty consolidation
A cash-flow cleanup deal that paid off: eliminating the Xolair royalty stream looks like a bargain now that Xolair is a multi-billion-dollar-a-year blockbuster.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Tanox Inc. (this deal) | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Affimed N.V. | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. | 2024 | $850M | — |
| Genentech, Inc. (Roche Group) / OMass Therapeutics Ltd. | 2025 | $420M | — |
| Genentech, Inc. (Roche Group) / MaxCyte, Inc. | 2026 | — | — |